Loading Events

Past Events › Grant

Events Search and Views Navigation

Event Views Navigation

October 2019

Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed)

October 28, 2019

Sponsor: NIH Common Fund Program
LOI Due Date: September 28, 2019
Application Deadline: October 28, 2019
Details: The goal of this funding opportunity announcement (FOA) for the Common Fund Program “Illuminating the Druggable Genome” (IDG; https://commonfund.nih.gov/idg/index) is to solicit applications for pilot projects on IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels) in order to study them beyond what the IDG’s Centers can accomplish and to validate and demonstrate the utility of IDG-generated reagents, data, and approaches.
Award:  Application budgets are limited to $100,000 in direct costs (excluding subcontract F&A) for one year and need to reflect the actual needs of the proposed project.

Find out more »

November 2019

American Fellowships: Summer/Short-Term Research Publication Grants

November 1, 2019

Sponsor: American Association of University Women Educational Foundation
Due Date: November 1, 2019
Award: $6,000 is available for an eight-week grant period.

Find out more »

Cycle 3: Prevention Research in Mid-Life Adults (R01)

November 5, 2019

Sponsor: National Institutes of Health
Due Date: November 5, 2019 by 5 pm local time of applicant
Award: Money, property, or both to carry out an approved project or activity. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The maximum grant period is five years.

Find out more »

NIH Cycles R01 and U01

November 5, 2019
|Recurring Event (See all)

One event on March 5, 2019 at 12:00 am

One event on November 5, 2019 at 12:00 am

NINDS Exploratory Clinical Trials (U01)
The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Budgets must reflect the actual needs; maximum request cannot exceed 5 years.
NINDS Efficacy Clinical Trials (U01)
he purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for  investigator-initiated clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS) to establish the efficacy (or compare the effectiveness) of treatment interventions. Budgets must reflect the actual needs; maximum request cannot exceed 5 years.
Promoting Research in Basic Neuroscience (R01)
The goal of this Funding Opportunity Announcement (FOA) is to stimulate research addressing fundamental questions in basic neuroscience. Budgets must reflect the actual needs; maximum request cannot exceed 5 years.
Prevention Research in Mid-Life Adults (R01)
This Funding Opportunity Announcement (FOA) seeks to stimulate research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and wellness as individuals age, and prevent illness and disability in later years. Budgets must reflect the actual needs; maximum request cannot exceed 5 years.
Pregnancy in Woman with Disabilities (R01)
Areas of interest also include studies to inform preconceptional and antenatal counseling and strategies for addressing barriers to prenatal care, and management of pregnancy, the puerperium, and the transition to parenthood in order to optimize outcomes for women with physical, intellectual and developmental, and/or sensory disabilities and their families. Application budgets are not limited but need to reflect the actual needs of the proposed project.

 

Find out more »

January 2020

Cycle 1: Whitehall Foundation Grants-In-Aid

January 1

Sponsor: Whitehall Foundation, Inc.
LOI Due Date: January 15, 2020
Application Due Date: June 1, 2020
Award: Grants-in-Aid are awarded for a one-year period and do not exceed $30,000.

Find out more »

Healthcare Research by Community Physicians

January 1

Sponsor: Physicans’ Services Incorporated Foundation

Due Date: Applications accepted on a rolling basis

Award: Grants up to $20,000 are available to cover the costs of the data gathering and analysis,
support staff and preparation of reports. Up to an additional $500 will be provided for travel
costs incurred in presenting papers on the results of a community practice study.

 

Find out more »

Cycle 2: NIH R41, R42, R43, R44, U43, U44

January 5

DUE DATE: JANUARY 5, 2020

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (SBIR)(R43/R44 Clinical Trial Not Allowed): This Funding Opportunity Announcement (FOA) which uses the STTR grant mechanism, will support to support the development of novel neuroscience tools and technologies in order to better understand the structure and function of brain circuits- a major goal of the BRAIN Initiative. This FOA will support further development of neurotechnologies developed through the BRAIN initiative or through other funding programs in preparation for commercial dissemination. According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics.

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (STTR)(R41/R42 Clinical Trial Not Allowed): The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research. Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II).

Find out more »

Cycle 1: Whitehall Foundation Research Grants

January 15

Sponsor: Whitehall Foundation, Inc.
LOI Due Date: January 15, 2020
Application Due Date: June 1, 2020
Award: Research grants normally range from $30,000 to $75,000 per year for up to three years.

Find out more »

February 2020

NIH R01 Cycles

February 5
|Recurring Event (See all)

One event on June 5, 2020 at 12:00 am

One event on October 5, 2020 at 12:00 am

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R01 Clinical Trial Optional):
The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimer’s disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. Application budgets are not limited but need to reflect the actual needs of the proposed project.

High Throughput Screening (HTS) to Discover Chemical Probes:
Encourages investigators to form collaborations with an established academic, nonprofit, or commercial high throughput screening (HTS) facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Preclinical Research on Model Organisms to Predict Treatment Outcomes for Disorders Associated with Intellectual and Developmental Disabilities:
Encourages applications from institutions/ organizations addressing preclinical research in model organisms of neurodevelopmental disorders. Budgets for direct costs of up to $499,999 per year may be requested.

Pregnancy in Women with Disabilities:
This FOA issued by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) encourages research project grants (R01) investigating the incidence, course, and outcomes of pregnancy among women with disabilities. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Prevention Research in Mid-Life Adults (R01 Clinical Trial Optional):
This Funding Opportunity Announcement (FOA) seeks to stimulate research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and well-being as individuals age and prevent illness and disability in later years.Application budgets are not limited but need to reflect the actual needs of the proposed project.

Promoting Research in Basic Neuroscience (R01 Clinical Trial Not Allowed):
he goal of this Funding Opportunity Announcement (FOA) is to stimulate research addressing fundamental questions in basic neuroscience. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Find out more »

NIH R21, R03

February 16
|Recurring Event (See all)

One event on February 16, 2020 at 12:00 am

One event on June 16, 2020 at 12:00 am

One event on October 16, 2020 at 12:00 am

DUE DATES: 

  • Cycle 3: October 16, 2019 by 5 PM of local organization time
  • Cycle 1: February 16, 2020 by 5 PM of local organization time
  • Cycle 2: June 16, 2020 by 5 PM of local organization time

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia: 
The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year.
Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)
The combined budget for direct costs for the two year project period may not exceed $200,000.
Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R21)
The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year.
Chronic Condition Self-Management in Children and Adolescents (R21 Clinical Trial Optional)
Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.

Find out more »

March 2020

AES Seed Grant Program 

March 23
|Recurring Event (See all)

One event on March 23, 2020 at 12:00 am

Sponsor: American Epilepsy Society
Due Date: September 22, 2019 or March 23, 2020
Award: The AES Seed Grant Program provides support to established investigators to pursue new and innovative directions in epilepsy research, bring new research methods to their research programs, or begin new collaborations with other investigators in epilepsy or in different, complementary disciplines. Seed Grants may provide up to $20,000 for one year for direct costs only, and they may not be renewed.

Find out more »

April 2020

Cycle 3: NIH R41, R42, R43, R44, U43, U44

April 5

DUE DATE: APRIL 5, 2020

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (SBIR)(R43/R44 Clinical Trial Not Allowed): This Funding Opportunity Announcement (FOA) which uses the STTR grant mechanism, will support to support the development of novel neuroscience tools and technologies in order to better understand the structure and function of brain circuits- a major goal of the BRAIN Initiative. This FOA will support further development of neurotechnologies developed through the BRAIN initiative or through other funding programs in preparation for commercial dissemination. According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics.

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (STTR)(R41/R42 Clinical Trial Not Allowed): The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research. Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II).

Find out more »

Cycle 1: Alzheimer’s Drug Discovery Foundation

April 10
|Recurring Event (See all)

One event on July 10, 2020 at 12:00 am

One event on October 9, 2020 at 12:00 am

LOI Due Dates:

  • Cycle 1: April 10, 2020
  • Cycle 2: July 10, 2020
  • Cycle 3: October 9, 2020

Drug Development Program
The goal of this RFP is to develop therapeutics for Alzheimer’s disease and related dementias. This RFP focuses on building preclinical evidence in animal models and on advancing lead molecules to the clinical candidate selection stage. Average Award: Up to $600,000 based on stage and scope of research.
Program to Accelerate Clinical Trials (PACT)
The goal of this RFP is to increase the number of innovative pharmacologic interventions tested in clinical studies for Alzheimer’s disease and related dementias. Average Award: Up to $3,000,000 based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.
Neuroimaging and CSF Biomarker Development Prgram
The aim of this RFP is to develop biomarkers for which there is a clear clinical need in Alzheimer’s disease and related dementias. Average award: Up to $600,000 based on stage and scope of research.
Prevention Beyond the Pipeline
The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Average awards: $50,000-$100,000 for epidemiological analyses, and u to $3,000,000 for clinical trials based on stage and scope of research.

Find out more »

May 2020

Child Neurology Shields Grant

May 1

Sponsor: Child Neurology Foundation
Due Date: May 1, 2020
Award: The Pediatric Epilepsy Research Foundation (PERF) Shields Research Grant supports translational or clinical research by a child neurologist or developmental pediatrician early in his/her academic career. The selected investigator will receive a $100,000 grant of $50,000 per year for two years.

Find out more »

AES Seed Grant Program 

May 4
|Recurring Event (See all)

One event on September 28, 2020 at 12:00 am

Sponsor: American Epilepsy Society
Due Dates: 

  • Cycle 1: May 4, 2020
  • Cycle 2: September 28, 2020

Award: The AES Seed Grant Program provides support to established investigators to pursue new and innovative directions in epilepsy research, bring new research methods to their research programs, or begin new collaborations with other investigators in epilepsy or in different, complementary disciplines. Seed Grants may provide up to $20,000 for one year for direct costs only, and they may not be renewed.

Find out more »

AES Research and Training Workshops

May 4
|Recurring Event (See all)

One event on September 23, 2020 at 12:00 am

Sponsor: American Epilepsy Society
Due Dates: 

  • Cycle 1: May 4, 2020
  • Cycle 2: September 23, 202o

Award: AES welcomes applications for funding to support scientific conferences and workshops focused on epilepsy research and training. Applications for workshop funding are reviewed by the AES Research and Training Council, and the number and amount of awards made each year are contingent on available funds.

Find out more »

ADDF-Harrington Scholar Program

May 18

Sponsor: Alzheimer’s Drug Discovery Foundation
LOI due date: May 18, 2020
Full Application due date: August 10, 2020
Award: Up to $600,000 over 2 years with dedicated support from a team of industry veterans with capabilities that include medicinal chemistry, pharmacology & toxicology, and business development. The ADDF-Harrington Scholar Program is dedicated to advancing academic discoveries into medicines for Alzheimer’s disease and related dementias.

Find out more »

BRAIN Initiative: Clinical Studies to Advance Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UH3)

May 23
|Recurring Event (See all)

One event on September 21, 2020 at 12:00 am

Sponsor: National Institutes of Health
LOI Due Dates: May 23, 2020, September 21, 2020
Application Deadlines: June 22, 2020, October 21, 2020
Award: The NIH anticipates providing $10M per year to fund an estimated 5 to 7 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. Budgets should rarely exceed $2M per year.The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue a small clinical trial to obtain critical information necessary to advance recording and/or stimulating devices to treat central nervous system disorders and better understand the human brain (e.g., Early Feasibility Study).

Find out more »

June 2020

NIH R01 Cycles

June 5
|Recurring Event (See all)

One event on June 5, 2020 at 12:00 am

One event on October 5, 2020 at 12:00 am

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R01 Clinical Trial Optional):
The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimer’s disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. Application budgets are not limited but need to reflect the actual needs of the proposed project.

High Throughput Screening (HTS) to Discover Chemical Probes:
Encourages investigators to form collaborations with an established academic, nonprofit, or commercial high throughput screening (HTS) facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Preclinical Research on Model Organisms to Predict Treatment Outcomes for Disorders Associated with Intellectual and Developmental Disabilities:
Encourages applications from institutions/ organizations addressing preclinical research in model organisms of neurodevelopmental disorders. Budgets for direct costs of up to $499,999 per year may be requested.

Pregnancy in Women with Disabilities:
This FOA issued by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) encourages research project grants (R01) investigating the incidence, course, and outcomes of pregnancy among women with disabilities. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Prevention Research in Mid-Life Adults (R01 Clinical Trial Optional):
This Funding Opportunity Announcement (FOA) seeks to stimulate research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and well-being as individuals age and prevent illness and disability in later years.Application budgets are not limited but need to reflect the actual needs of the proposed project.

Promoting Research in Basic Neuroscience (R01 Clinical Trial Not Allowed):
he goal of this Funding Opportunity Announcement (FOA) is to stimulate research addressing fundamental questions in basic neuroscience. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Find out more »

NIH R21, R03

June 16
|Recurring Event (See all)

One event on February 16, 2020 at 12:00 am

One event on June 16, 2020 at 12:00 am

One event on October 16, 2020 at 12:00 am

DUE DATES: 

  • Cycle 3: October 16, 2019 by 5 PM of local organization time
  • Cycle 1: February 16, 2020 by 5 PM of local organization time
  • Cycle 2: June 16, 2020 by 5 PM of local organization time

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia: 
The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year.
Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)
The combined budget for direct costs for the two year project period may not exceed $200,000.
Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R21)
The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year.
Chronic Condition Self-Management in Children and Adolescents (R21 Clinical Trial Optional)
Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.

Find out more »
+ Export Events